Despite FDA Reservations, ODAC Votes Yes On Schering's PegIntron And GSK's Votrient

05 Oct 2009

• By The Pink Sheet Daily

The panel voted 6-4 to recommend approval of the sBLA for PegIntron (peginterferon alfa-2b) for melanoma, and unanimously for Glaxo's Votrient (pazopanib) for advanced renal cell carcinoma.

Despite FDA Reservations, ODAC Votes Yes On Schering's PegIntron And GSK's Votrient

More from Archive

More from Pink Sheet